clinical trial · NCT04221542
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostate CancerAMG 509AbirateroneEnzalutamide
brief summary
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 are open to accrual.
started
Mar 4, 2020
primary completion
Mar 22, 2030
completion
Mar 21, 2032
last updated
May 29, 2026
official title
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol